Daiichi initiates pivotal trials for cancer drug nimotuzumab

04/26/2013 | Pharmaceutical Business Review Online

Daiichi Sankyo has started patient enrollment for two late-stage trials of nimotuzumab, its experimental drug for lung and gastric cancer. Nimotuzumab is a recombinant humanized monoclonal antibody that targets the epidermal growth factor receptor. The lung cancer trial will be carried out in Japan while the gastric cancer study will be conducted in Japan and South Korea.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX